Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EM1033
- Development stage
- Preclinical
- Lead developer
- EpimAb Biotherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
EM1033 is a protease-activated bispecific T-cell engager (TCE) developed by EpimAb Biotherapeutics for the treatment of solid tumors. Utilizing EpimAb's proprietary ProTCE platform, EM1033 is designed to target CD228 (melanoma-associated antigen p97) and CD3. The molecule is engineered to remain in an inactive state in systemic circulation and undergo conditional activation by proteases specifically found within the tumor microenvironment. This approach aims to broaden the therapeutic window by reducing off-tumor, on-target toxicities while facilitating potent T-cell mediated destruction of CD228-expressing cancer cells. As of 2024, the program is in the IND-enabling/preclinical stage of development.
- Other names
- ProTCE
02
Targets
CD3 (T-cell surface glycoprotein CD3)MELTF (Melanotransferrin)
Beyond the preview
Go deeper on EM1033.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EM1033.